Early Paxlovid treatment was associated with modestly lower risks of Long COVID, post-acute hospitalization, and death among high-risk, nonhospitalized patients with COVID-19, while no clear reduction in Long COVID risk was observed among low-risk patients.
Article URL: https://plos.io/4z20PvX
Article Title: Real-world effectiveness of Paxlovid in protecting Long COVID for outpatient adult patients: A target trial emulation study from the RECOVER Initiative
Author countries: United States
Funding: This research was funded by the National Institutes of Health (NIH) Agreement OTA. OT2HL161847 (contract number EHR-01-21 to all) as part of the Researching COVID to Enhance Recovery (RECOVER) research program and the National Institute of Health (grant number RF1AG084178, R01HD120978 to F.W. and C.Z.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the RECOVER Program, the NIH or other funders.
